[Federal Register Volume 77, Number 199 (Monday, October 15, 2012)]
[Notices]
[Pages 62515-62516]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-25251]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-13-0612]
Proposed Data Collections Submitted for Public Comment and
Recommendations
In compliance with the requirement of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) will publish periodic summaries of proposed projects.
To request more information on the proposed projects or to obtain a
copy of the data collection plans and instruments, call 404-639-7570
and send comments to Ronald Otten, CDC Reports Clearance Officer, 1600
Clifton Road, MS-D74, Atlanta, GA 30333 or send an email to
[email protected].
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology. Written comments should be received
within 60 days of this notice.
Proposed Project
Well-Integrated Screening and Evaluation for Women Across the
Nation (WISEWOMAN) Reporting System (OMB 0920-0612, exp. 3/31/
2013)--Extension--National Center for Chronic Disease Prevention and
Health Promotion (NCCDPHP), Centers for Disease Control and Prevention
(CDC).
Background and Brief Description
Cardiovascular disease (CVD), which includes heart disease,
myocardial infarction, and stroke, is the leading cause of death for
women in the United States, and is largely preventable. The WISEWOMAN
program (Well-Integrated Screening and Evaluation for Women Across the
Nation), administered by the Centers for Disease Control and Prevention
(CDC), was established to examine ways to improve the delivery of
services for women who have limited access to health care and elevated
risk factors for CVD. The program focuses on reducing CVD risk factors
and provides screening services for select risk factors such as
elevated blood cholesterol, hypertension and abnormal blood glucose
levels. The program also provides lifestyle interventions and medical
referrals. On an annual basis, 21 grantees funded through the WISEWOMAN
program have provided services to approximately 30,000 women who are
already participating in the National Breast and Cervical Cancer Early
Detection Program (NBCCEDP), also administered by CDC.
CDC currently collects information from WISEWOMAN grantees to
support continuous program monitoring and improvement activities. CDC
seeks to extend OMB approval for one additional year. There are no
changes to the number of respondents, the data items reported to CDC,
the estimated burden per response, or the total estimated annualized
burden. All information will continue to be collected twice per year.
Information reported to CDC includes baseline and follow-up data
(12 months post enrollment) for all women served through the WISEWOMAN
program. These data, called the minimum data elements (MDE), include
data elements that describe risk factors for the women served in each
program and data elements that describe the number and type of
intervention sessions attended. Funded grantees compile the data from
their existing databases and report the MDE to CDC on April 15th and
October 15th of each year.
The MDE data provide an assessment of how effective the WISEWOMAN
program is at reducing the burden of cardiovascular disease risk
factors among women who utilize program services. The information
collected from grantees is also used to assess the cost-effectiveness
and impact of the program. Because certain demographic information has
already been collected as part of NBCCEDP, the additional burden of
WISEWOMAN program reporting is modest.
The overall program evaluation is designed to demonstrate how
WISEWOMAN can obtain more complete health data on vulnerable
populations, promote public education about disease incidence and risk-
factors, improve the availability of screening and diagnostic services
for under-served women, ensure the quality of services provided to
under-served women, and develop strategies for improved interventions.
The information reported to CDC also includes programmatic information
related to grantee management, public education and outreach,
professional education, service delivery, cost, and progress toward
meeting stated programmatic objectives.
All MDE information will be submitted to CDC electronically. The
estimated burden per response for Screening and Assessment MDE is 16
hours. The estimated burden per response for Lifestyle Intervention MDE
is 8 hours. Progress reports will be submitted in hardcopy format. The
estimated burden per response for each progress report is 16 hours.
[[Page 62516]]
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per Total burden
Type of respondent Form name respondents responses per response (in (in hr)
respondent hr)
----------------------------------------------------------------------------------------------------------------
WISEWOMAN Grantees............ Screening and 21 2 16 672
Assessment MDE.
Lifestyle 21 2 8 336
Intervention
MDE.
Progress Report. 21 2 16 672
---------------------------------------------------------------
Total..................... ................ .............. .............. .............. 1,680
----------------------------------------------------------------------------------------------------------------
Dated: October 9, 2012.
Ron A. Otten,
Director, Office of Scientific Integrity (OSI), Office of the Associate
Director for Science (OADS), Office of the Director, Centers for
Disease Control and Prevention.
[FR Doc. 2012-25251 Filed 10-12-12; 8:45 am]
BILLING CODE 4163-18-P